All In Biotech

Drug Trial Radar · NCT07871409

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Jun 16, 2027

Study completion Sep 8, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Conditions

  • Obesity
  • Overweight

Interventions

  • Maridebart cafraglutideDrug

    Administered subcutaneously.

  • AutoinjectorDevice

    The AI will be used by participants to self-administer SC doses of maridebart cafraglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home AdministrationTime frame: Weeks 12, 16, and 20
  2. Percentage of Participants Who Successfully Self-inject a Full Dose Among All Participants Who Entered the Home Self-administration Phase at Each Scheduled Home AdministrationTime frame: Weeks 12, 16, and 20

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Apex Clinical Research

    San Diego, California · Recruiting

  • Southern Clinical Research

    Miami, Florida · Recruiting

  • Research Institute of South Florida

    Miami, Florida · Recruiting

  • Clinical Neuroscience Solutions LLC

    Orlando, Florida · Recruiting

  • Florida Institute for Clinical Research

    Orlando, Florida · Recruiting

  • Charter Research - The Villages

    The Villages, Florida · Recruiting

  • Nsc Research

    Johns Creek, Georgia · Recruiting

  • North Georgia Clinical Research

    Woodstock, Georgia · Recruiting

  • Solaris Clinical Research

    Meridian, Idaho · Recruiting

  • Alliance For Multispecialty Research - Oak Brook

    Oak Brook, Illinois · Recruiting

  • Flourish Research

    Bowie, Maryland · Recruiting

  • Rochester Clinical Research

    Rochester, New York · Recruiting

  • Centricity Research

    Morehead City, North Carolina · Recruiting

  • Centricity Research Dublin

    Columbus, Ohio · Recruiting

  • Epic Medical Research - Oklahoma

    Chickasha, Oklahoma · Recruiting

  • Tribe Clinical Research LLC Dba Mountain View Clinical Research

    Greenville, South Carolina · Recruiting

  • Cedar Health Research- Texas Native Health

    Dallas, Texas · Recruiting

  • Cedar Health Research, LLC

    Dallas, Texas · Recruiting

  • Soma Clinical Trials, LLC

    Denison, Texas · Recruiting

  • Epic Medical Research - Red Oak

    DeSoto, Texas · Recruiting

  • Biopharma Informatic, LLC

    Houston, Texas · Recruiting

  • Research Physicians Network LLC

    Houston, Texas · Recruiting

  • Texas Institute of Cardiology

    McKinney, Texas · Recruiting

  • North Hills Medical Research

    North Richland Hills, Texas · Recruiting

  • Latin Clinical Trial Center

    San Juan, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.